Trial Watch: experimental TLR7/TLR8 agonists for oncological indications

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications

Resiquimod (R848) and motolimod (VTX-2337) are second-generation experimental derivatives of imiquimod, an imidazoquinoline with immunostimulatory properties originally approved by the US Food and Drug Administration for the topical treatment of actinic keratosis and genital warts more than 20 years...

Full description

Bibliographic Details
Main Authors: Giorgio Frega, Qi Wu, Julie Le Naour, Erika Vacchelli, Lorenzo Galluzzi, Guido Kroemer, Oliver Kepp
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
cancer immunotherapy
cgas
danger signaling
immune checkpoint blockers
immunogenic cell death
type i interferon
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1796002

Internet

http://dx.doi.org/10.1080/2162402X.2020.1796002

Similar Items